Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis

Recent Patents on Anti-Infective Drug Discovery

Volumn 7, Issue 2, 2012, Pages 141-156

  Cheepsattayakorn, Attapon ^a   Cheepsattayakorn, Ruangrong ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Compounds; Extensively drug; Multidrug; Novel; Patents; Resistant; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; DELAMANID; ETHAMBUTOL; GATIFLOXACIN; IMIPENEM; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PLACEBO; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; THIOAMIDE; UNINDEXED DRUG;

ABDOMINAL PAIN; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTERIAL CLEARANCE; CROSS RESISTANCE; DEPRESSION; DIARRHEA; DIRECTLY OBSERVED THERAPY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG STRUCTURE; ELECTROLYTE DISTURBANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GASTRITIS; HEARING DISORDER; HUMAN; HYPOTHYROIDISM; KIDNEY FAILURE; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; SEIZURE; SINGLE DRUG DOSE; SLEEP DISORDER; SPUTUM CULTURE; SPUTUM SMEAR; TINNITUS; TOXIC HEPATITIS; TUBERCULOSIS; VERTIGO; VISUAL DISORDER;

ANIMALS; ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PATENTS AS TOPIC;

EID: 84863919123     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489112801619683     Document Type: Article

References (129)

1. Loddenkemper R, Sagebiel D, Brendel A. Strategies against multidrug-resistant tuberculosis. Eur Respir J 2002; 20 (Suppl 36): 66s-77s.
2. Caminero JA. Assessing the level of drug resistance in TB patients: What is the pattern of Resistance. Africa Health 2009; 14-7.
3. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Eng J Med 1993; 329 (9): 784-91.
4. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Teatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampicin. N Eng J Med 1993; 328 (8): 527-32.
5. Costello HD, Caras GJ, Snider DE Jr. Drug resistance among previously treated tuberculosis patients, a breif report. Am Rev Respir Dis 1980; 121 (2): 313-6.
6. World Health Organization. Management of MDR-TB: A field guide. WHO/HTM/TB/2008.402a. Geneva, Switzerland: WHO, 2009.
7. Caminero JA, de March P. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. Am J RespirCrit Care Med 2004; 169 (2): 316-7.
8. Caminero JA. Management of multidrug-resistant tuberculosis and patients in retreatment. Eur Respir J 2005; 25 (5): 928-36.
9. Caminero JA. Number of drugs to treat multidrug-resistant tuberculosis. From the authors. Am J Respir Crit Care Med 2004; 169 (12): 1337.
10. Iseman MD. Statements of ATS, CDC, and IDSA on treatment of tuberculosis. From the authors. Am J Respir Crit Care Med 2004; 169 (2): 317.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
12. Caminero JA. Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int JTuberc Lung Dis 2006; 10 (8): 829-37.
13. Ormerod LP. Multidrug-resistant (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 2005; 73-74 (1): 17-24.
14. Donald PR, Parkin DP, Seifart HI, Schaaf HS, Van Helden PD, Werely CJ, et al. The influence dose and N-acetyltranferase-2 (NAT 2) genotype and phenotype on pharmacokinetics and pharmacodynamics of isoniazid. Eur JClinPharmacol 2007; 63 (7): 633-9.
15. rd, Stover CK. AhpC, oxidative stress and drug resistance in Mycobacterium tuberculosis. Biofactors 1999; 10(2-3): 211-7.
16. Silva MSN, Senna SG, Ribeiro MO, Valim ARM, Telles MA, Kritski A, et al. Mutations inkatG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2003; 41 (9): 4471-4.
17. Costa ERD, Ribeiro M, Silva MSN, Arnold LS, Rostirolla DC, Cafrune PI, et al. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. MMC Microbiology 2009; 9: 39. Available at: http://www.biomedcentral.com/1471-2180/9/39, accessed on April 2, 2012.
18. Lee ASG, Teo ASM, Wong SY. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2001; 45 (7): 2157-9.
19. Zhang Y, Yew WW. Mechanism of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13 (11): 1320-30.
20. Sintchenko V, Jelfs PJ, Chew WK, Gilbert GL. Mycobacterium tuberculosisrpoB gene DNA sequencing: implications for detection of rifamycin resistance. J AntimicrobChemother 1999; 44(2): 294-5.
21. Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C, et al. Acquired rifamycin resistance with twice weekly treatment of HIVrelated tuberculosis. Am JRespirCrit Care Med 2006; 173 (3): 350-6.
22. Singh R, Meena RA, Meena LS. Multidrug-resistant and extensively drug-resistant TB: a nuisance to medical sciences. J BacyeriolParasitol 2011; 2(1): 1-5.
23. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Beverly M, Starks AM, et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob AgentsChemother2011; 55 (5): 2032-41.
24. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutatoions associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systemic revierw. PLoS ONE 2012; 7(3): e33275.
25. Khanna A, Raj VS, Tarai B, Sood R, Pareek PK, Upadhyay DJ, et al. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi region in India. Antimicrob Agents Chemother 2010; 54 (11): 4789-93.
26. Jugheli L, Bzekalava N, RijkPde, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close region with mutations in the rrs gene. Antimicrob Agents Chemother 2009; 53 (12): 5064-8.
27. Zaunbrecher MA, Sikes Jr RD, Metchock B, Shinnick TM, Posey JE. Overexpression of the chromosomally encoded aminoglycoside acetyltransferaseeis confers kanamycin resistance in Mycobacterium tuberculosis. PNAS 2009; 106 (47). Available at http://www.pnas.org/cgi/content/full/0907925106/DCSupplemental, accessed on April 2, 2012.
28. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, et al. SQ109 target MmpL3, a membrane transporter of trehalosemonomycolateinvoleved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Amtimicrob Agents Chemother 2012; 56 (4): 1797-809.
29. rd CE, Blanchard JS. The chemical biology of new drugs in development for tuberculosis. Curr Opin Chem Biol 2010; 14(4): 456-66.
30. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubochi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006; 3(11): e466.
31. Shakya N, Agrawal B, Kumar R. Chemotherapeutic strategies and targets against resistant TB. In: Pere-Joan Cardona, Ed. Understanding tuberculosis-new approaches to fighting against drug resistance. Rijeka:InTech Publisher 2012: 33-92.
32. Feuerriegel, Köser CU, Bau D, Rosch-Gerdes S, Summers DK, Archer JAC, et al. Impact offgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Amtimicrob Agents Chemother 2011; 55 (12): 5718-22.
33. 420-dependent Glucose-6-phosphate dehydrogenase FGD1 involved in the activity of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. J Biol-Chem 2008; 283 (25): 17531-41.
34. John R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug resistance in Mycobacterium tuberculosis. Curr IssuesMolBiol 2006; 8(2): 97-111.
35. Shaw KJ, Barbachyn MR. The oxazolidinones: past, present, and future. Ann N Y AcadSci2011; 1241(1): 48-70.
36. Villewagne B, Crauste C, Flipo M, Baulard A, Deprez B, Willard N. Tuberculosis: The drug development pipeline at glance. Eur J Med Chem 2012. Available online: 25 February 2012, at: http://www.sciencedirect.com/science/journal/02235234
37. Kaneko T, Cooper C, Mdluli K. Challenges and opportunities in developing novel drugs for TB. Future Med Chem 2011; 3 (11): 1373-400.
38. rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drugresistant Mycobacterium tuberculosis. Science 2009; 323 (5918): 1215-8.
39. Veziris N, Truffot C, Mainardi JL, Jarlier V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agent Chemother 2011; 55 (6): 2597-600.
40. Pascal MR, Degiacomi G, RibeiroALdeJL, Zara F, Mori PDe, Heym B, et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 2010; 54 (4): 1616-8.
41. Makarov V, Manina G, Mikusova K, Mollmann U, Ryabova O, Saint-Joanis B, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009; 324 (5928): 801-4.
42. Caceres NE, Harris NB, Wellehan JF, Feng Z, Kapur V, Barletta RG. Overexpression of the D-alanine racemase gene confers resistance to D-cycloserine in Mycobacterium smegmatis. J Bacteriol 1997; 179 (16): 5046-55.
43. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J AnitimicrobChemother 2012; 67(2): 290-8.
44. Xu HB, Jiang RH, Tang SJ, Li L, Xiao HP. Role ofclofazimine in the treatment of multidrug-resistant tuberculosis: A retrospective observational cohort assessment. J Anitmicrob Chemother 2012 Mar 5. [Epub ahead of print].
45. Nathason E, Weezenbeek CL, Rich ML, Gupta R, Bayona J, Blöndal K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis 2006; 12 (9): 1389-97.
46. Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrugresistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8 (11): 1382-4.
47. Somasundaram S, Paramasivan NC. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 2006; 52 (4): 190-5.
48. Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010; 15 (5): 764-78.
49. Laurenzi M, Ginsberg A, Spigelman M. Challenges associated with current and future TB treatment. Infect DisordDrug Targets 2007; 7 (2): 105-19.
50. TB Online-Moxifloxacin. Available at: http://www.tbonline. info/posts/2011/8/23/moxifloxacin/, accessed on May 5, 2012.
51. Castellin, A., Padovan, P., Jiageng, L., Zhou, Y., Feng, L. Process for preparing moxifloxacin and salts thereof. US20110230661 (2011).
52. Rao, D.R., Kankan, R.N., Pathi, S.L., Puppala, R., Gangrade, M., Kanathala, S. Process for the synthesis of moxifloxacin hydrochloride. US20100152229 (2010).
53. Czarnik, A.W. Deuterium-enriched moxifloxacin. US20080306105 (2008).
54. Cosme, G., Javier, V.P., Francisco, P.N. Crystalline form of gatifloxacin. US10573329 (2007).
55. th edition, Published by Merck & Co. Inc., 1983-2002: 297-99, 1179, 2979.
56. Hugonnet JE, Blanchard JS. Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry 2007; 46 (43): 11998-2004.
57. Blanchard, J.S. Method for treating tuberculosis. US20110190253 (2011).
58. Ginsberg AM, Laurenzi MW, Rouse DJ, Whiney KD, Spigelman MK. Safety, tolerabiblity, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob AgentsChemother 2009; 53 (9): 3720-5.
59. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, et al. Bacterial activity of nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 2005; 49 (6): 2289-93.
60. Ahmad Z, Peloquin CA, Singh RP, Derendorf H, Tyagi S, Ginsberg A, et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55 (1): 239-45.
61. Ginsberg AM. Drugs in development for tuberculosis. Drugs 2010; 70 (17): 2201-14.
62. Hutson S. Half-century-old TB drugs get a facelift in new cocktails. Nat Med 2010; 16 (12): 1346.
63. Working Group on New TB Drugs 2011. Available athttp://www.newtbdrugs.org/project.php?id=25, accessed on December 2, 2011.
64. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54 (8): 3402-7.
65. Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother 2010; 54 (4): 1436-42.
66. Thompson, A.M., Denny, W.A., Blaser, A., Ma, Z. Nitroimidazooxazine andnitroimidazooxazole analogues and their uses. US2010/043908 (2010).
67. Anonymous OPC-67683. Tuberculosis (Edinb) 2008; 88 (2): 132-3.
68. Singh R, Manjunatha U, Boshoff HIM, Ha YH, Niyomrattanakit P, Ledwidge R, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322 (5906): 1392-5.
69. Denny, W.A., Thompson, A.M., Blaser, A., Palmer, B.D., Ma, Z., Sutherland, H.S., Kmentova, I. Nitroimidazooxazines and their uses in anti-tubercular therapy. US20120028973 (2012).
70. Brickner, S.J., Nuermberger, E., Stover C.K. Combination therapy for tuberculosis. US20110190199 (2011).
71. MoelleringJr RC. Linezolid: the firstoxazolidinone antimicrobial. Ann Intern Med 2003; 138 (2): 135-42.
72. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58 (3): 701-4.
73. Via LE (Contact Person), ClinicalTrials. gov identifier: NCT00727844, Study ID Number: 999908167, 08-1-N167, Location: National Masan TB Hospital, Republic of Korea (Recruiting), Study first received: August 1, 2008, Last Updated: December 2, 2010, ClinicalTrials. gov processed this record on March 31, 2011. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00727844, accessed on April 5, 2011.
74. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Jimenez I, Royo G. Mutant prevention concentration: comparison offluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53 (3): 441-4.
75. Rao, D.M., Reddy, P.K. Novel crystalline form of linezolid. US7718799 (2010).
76. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360 (6): 2397-405.
77. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011; 6 (3): e 17556.
78. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55 (12): 5485-92.
79. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360 (23): 2397-405.
80. Grossman, T.H., Locher, C. Compositions of n-benzyl-3-(4-chlorophenyl)-2-[methyl-[2-oxo-2(3,4,5 trimoxyphenyl)acetyl] amino]-n-[3-(4-pyridyl)-1-[2-4-pyridyl)ethyl]propyl]propranolamide and uses thereof. US20110065723 (2011).
81. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56 (11): 968-74.
82. Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br J Pharmacol 2005; 144 (1): 80-7.
83. Available at: http://www.sequella.com/docs/Sequella_1sheet09v2_SQ109.pdf accessed on January 2, 2010.
84. Protopopova, M.N., Nikoneneko, B., Chen, P. Anti-tubercular drugs: Compositions and methods. US12255976 (2009).
85. Jeminez E. The tuberculosis pipeline introduction. In:Clayden P, Chou L, Collins S, Harrington M, Jefferys R, Jiminez E, Morgan S, Swan T, Syed J, Wingfield C, Eds. Treatment Action Group 2010 Pipeline Report. London: TAG 2010: 101-48.
86. Barbachyn MR, Hutchinson DK, Brickner SJ, Cynamon MH, Kilburn JO, Klemens SP, et al. Identification of a novel oxazolidinone (PNU-100480) with potent antimycobacterial activity. J Med Chem 1996; 39 (3): 680-5.
87. Sood R, Rao M, Singhal S, Rattan. Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterial tuberculosis infected murine macrophages. Int JAntimicrob Agents 2005; 25 (6): 464-8.
88. Vera-Cabrera L, Castro-Garza J, Rendon A, Ocampo-Candiani J, Welsh O, Choi SH, et al. In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867. Antimicrob Agents Chemother 2005; 49 (10): 4351-3.
89. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 219, 2009.
90. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 2012; 7 (1): e30479.
91. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, et al. Biomarker-assist dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55 (2): 567-74.
92. Das, K., Melnick, D.A., Radha, S. Compound for the treatment of tuberculosis. US20120035219 (2012).
93. Makarov VA, Manina G, Mikusova K, Möllmann U, Ryabova O, Saint-Joanis B, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009; 324 (5928): 801-4.
94. Makarov, V.A., Cole, S.T., Moellmann, U. Benzothiazinone derivatives and their use as antibacterial agents. US7863268 (2011).
95. Khalaf I, Vlase L, Lazar D, Corciova A, Ivanescu B, Lazar MI. HPLC-MS study of phytoestrogens from Glycyrrhizaglabra. Farmacia 2010; 58 (1): 89-94.
96. Gupta VK, Fatima A, Faridi U, Negi AS, Shanker K, Kumar JK, et al. Antimicrobial potential of Glycyrrhizaglabra roots. JEthnopharmacol 2008; 116 (2): 377-80.
97. Baker, W.R., Mitscher, L.A. Isoflavonoid antibacterial compounds, compositions and use. US5399558 (1995).
98. Fanciulli M, Gentile FP, Bruno T, Paggi MG, Benassi M, Floridi A. Inhibition of membrane redox activity by rhein and adriamycin in human glioma cells. Anticancer Drugs 1992; 3 (6): 615-21.
99. Agarwal SK, Sudhir SS, Sushma V, Sushil K. Antifungal activity of anthraquinone derivatives from Rheum emodi. J Ethnopharmacol 2000; 72 (1-2): 43-6.
100. Gow-Chin Y, Pin-Der D, Da-Yon C. Antioxidant activity of anthraquinones and anthrone. Food Chem 2000; 70 (4): 437-41.
101. Zhi-Heng H, Ming-Fang H, Shuang-Cheng M, Paul PHB. Antiangiogenic effects of rhubarb and its anthraquinone derivatives. J Ethnopharmacol2009; 121 (2): 313-7.
102. Gavit RS, Laddha KS. Synthesis of 4, 5-dihydroxy-9, 10-dioxoanthracene-2-benzyl carboxylate ester from rhein. Inte J Pharmacolog Sci Res 2010; 1 (10): 60-4.
103. Vittori, N., Collins, M. Production ofrhein and rhein derivatives. US5652265 (1997).
104. Springolo, V. Galenic formulations for oral use of rhein derivatives with delayed release for therapeutical use. US4861599 (2010).
105. Marriner GA, Nayyar A, Uh E, Wong SY, Mukherjee T, Via LE, et al. The medicinal chemistry of tuberculosis chemotherapy. In: Elliott RL, Ed. Topics in medicinal chemistry 7. London: Springer 2011: 47-124.
106. Takahashi, Y., Igarashi, M., Okada, M. Anti-XDR-TB drug, anti-MDR-TB drug, and combination anti-tuberculosis drug. US20110237530 (2011).
107. Singh KP, Gillespie SH. Fluoroquinolones in the management of tuberculosis. In:Donald PR, van Helden PD, Eds. Antituberculosis chemotherapy. Basel: KARGER 2011: 51-60.
108. Bogatcheva E, Hanrahan C, Nikonenko B, de los Santos G, Reddy V, Chen P, et al. Identification of SQ609 as a compound from a library of dipiperidines. Bioorg MedChemLett 2011; 21 (18): 5353-7.
109. Portero JL, Rubio M. New anti-tuberculosis therapies. Expert OpinTheraPat 2007; 17 (6): 617-37.
110. Venkata, V., Nikolaeva, P.M., Elena, B. Compositions and methods comprising capuramycin analogues. US12331929 (2009).
111. Bijev A, Georgieva M. The development of new tuberculostatics addressing the return of tuberculosis: Current status and trends (review). Journal of the University of Chemistry Technology and Metallurgy 2010; 45 (2): 111-26.
112. Hudson A, Imamura T, Gutteridge W, Kanyok T, Nunn P. The current anti-TB drug research and development pipeline. UNDP/World Bank/WHO, Special Programme for Research and Training in Tropical Diseases (TDR) 2003: 1-44.
113. Wingfield C. TB coinfection: Tuberculosis treatment pipeline. HIV Treatment Bullet 2010, July.
114. Adhvaryu M, Vakharia B. Drug-resistant tuberculosis: Emerging treatment options. Clin Pharmacol 2011; 3: 51-67. [Epub 2011 Dec 14].
115. Ingen J van, Boeree MJ, Wright A, Laan T van der, Dekhuijzen PNR, Soolingen D van. Second-line drug resistance in multidrugresistant tuberculosis cases of various origins in the Netherlands. Int J Tuberc Lung Dis 2008; 12(11): 1295-9.
116. Zamecnik, P.C., Tabatadze, D. New modalities for treatment of drug-resistant tuberculosis and other diseases. WO2010030751 (2010).
117. Fussenegger, M., Weber, W., Schoenmakers, R. Composition for treatment of tuberculosis. US20110053880A1 (2011).
118. Fussenegger, M., Weber, W., Schoenmakers, R. Composition for treatment of tuberculosis. WO2009080432A2 (2009).
119. DR-TB drugs under the microscope. Available at: http://www.msfaccess.org, accessed on April 5, 2011.
120. Blanc L, Falzon D, Fitzpatrick C, Floyd K, Garcia I, Gilpin C, et al. Global tuberculosis control: WHO report 2010. [Onine]. Geneva: World Health Organization; 2010. [accessed March 14, 2011]. Available at: http://whqlibdoc.who.int/publications/2010/9789241564069 eng.pdf
121. Coyne KM, Pozniak AL, Lamorde M, Boffito M. Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 2009; 23 (4): 437-46.
122. TDR. Childhood tuberculosis: Addressing a forgotten crisis. [Online] January 14, 2011. [accessed March 14, 2011]. Available at: http://apps.who.int/tdr/svc/news-events/news/paediatric-tb
123. Pandey R, Khuller GK. Antitubercular inhaled therapy: Opportunities, progress and challenges. J Antimicrob Chemother 2005; 55 (4): 430-5.
124. Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Phar Res 2008; 25 (4): 805-11.
125. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 2005; 172 (2): 1487-90.
126. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulatedantitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis (Edin) 2003; 83 (6): 373-8.
127. Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother 2004; 54 (1): 266-8.
128. Hari BNV, Chitra KP, Bhimavarapu R, Karunakaran P, Muthukrishanan N, Rani SBS, et al. Novel technologies: A weapon against tuberculosis. Indian J Pharmacol 2010; 42 (6): 338-44.
129. Grosset J. Mycobacterium tuberculosis in the extracellular compartment: An underestimated adversary. Antimicrob Agents Chemother 2003; 47 (3): 833-6.